Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast with Low Dose ICS in Chronic Asthma
NCT00163527Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2003
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of roflumilast in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in Forced Expiratory Volume in 1 Second at 24 weeks. Started Apr 2003; status: completed.
02
Drugs
roflumilast
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00163527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163527.